NO320296B1 - Oral suspensjon - Google Patents

Oral suspensjon Download PDF

Info

Publication number
NO320296B1
NO320296B1 NO20015755A NO20015755A NO320296B1 NO 320296 B1 NO320296 B1 NO 320296B1 NO 20015755 A NO20015755 A NO 20015755A NO 20015755 A NO20015755 A NO 20015755A NO 320296 B1 NO320296 B1 NO 320296B1
Authority
NO
Norway
Prior art keywords
suspension
ziprasidone
acid
polysorbate
silicon dioxide
Prior art date
Application number
NO20015755A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015755D0 (no
NO20015755L (no
Inventor
Daniel Ray Arenson
Hong Qi
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22472103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO320296(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20015755D0 publication Critical patent/NO20015755D0/no
Publication of NO20015755L publication Critical patent/NO20015755L/no
Publication of NO320296B1 publication Critical patent/NO320296B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Colloid Chemistry (AREA)
  • Cosmetics (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Dental Preparations (AREA)
NO20015755A 1999-05-27 2001-11-26 Oral suspensjon NO320296B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13626899P 1999-05-27 1999-05-27
PCT/IB2000/000593 WO2000072847A1 (en) 1999-05-27 2000-05-08 Ziprasidone suspension

Publications (3)

Publication Number Publication Date
NO20015755D0 NO20015755D0 (no) 2001-11-26
NO20015755L NO20015755L (no) 2002-01-23
NO320296B1 true NO320296B1 (no) 2005-11-21

Family

ID=22472103

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015755A NO320296B1 (no) 1999-05-27 2001-11-26 Oral suspensjon

Country Status (50)

Country Link
EP (1) EP1181018B1 (zh)
JP (1) JP3942827B2 (zh)
KR (1) KR100477782B1 (zh)
CN (1) CN1196486C (zh)
AP (1) AP1409A (zh)
AR (1) AR022643A1 (zh)
AT (1) ATE234097T1 (zh)
AU (1) AU777413B2 (zh)
BG (1) BG65367B1 (zh)
BR (1) BR0010990A (zh)
CA (1) CA2371550C (zh)
CO (1) CO5170458A1 (zh)
CR (1) CR6506A (zh)
CU (1) CU23223B7 (zh)
CZ (1) CZ20014230A3 (zh)
DE (1) DE60001649T2 (zh)
DK (1) DK1181018T3 (zh)
DZ (1) DZ3049A1 (zh)
EA (1) EA003907B1 (zh)
EE (1) EE04704B1 (zh)
ES (1) ES2191618T3 (zh)
GC (1) GC0000190A (zh)
GE (1) GEP20033113B (zh)
GT (1) GT200000081A (zh)
HK (1) HK1046366B (zh)
HN (1) HN2000000071A (zh)
HR (1) HRP20010878B1 (zh)
HU (1) HUP0201297A3 (zh)
IL (2) IL145950A0 (zh)
IS (1) IS2396B (zh)
MA (1) MA26741A1 (zh)
MX (1) MXPA01012124A (zh)
MY (1) MY127891A (zh)
NO (1) NO320296B1 (zh)
NZ (1) NZ514764A (zh)
OA (1) OA11946A (zh)
PA (1) PA8495801A1 (zh)
PE (1) PE20010127A1 (zh)
PL (1) PL196867B1 (zh)
RS (1) RS50089B (zh)
SI (1) SI1181018T1 (zh)
SK (1) SK284590B6 (zh)
SV (1) SV2001000085A (zh)
TN (1) TNSN00112A1 (zh)
TR (1) TR200103392T2 (zh)
TW (1) TWI263498B (zh)
UA (1) UA59491C2 (zh)
UY (1) UY26166A1 (zh)
WO (1) WO2000072847A1 (zh)
ZA (1) ZA200109692B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7175855B1 (en) 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
WO2002036099A1 (en) 2000-10-30 2002-05-10 Euro-Celtique S.A. Controlled release hydrocodone formulations
PL212421B1 (pl) * 2002-03-12 2012-09-28 Bristol Myers Squibb Co Kompozycja farmaceutyczna w postaci zawiesiny kwasowego leku i sposób jej wytwarzania oraz sposób maskowania gorzkiego lub innego nieprzyjemnego smaku leku
EP1575616A2 (en) * 2002-10-25 2005-09-21 Pfizer Products Inc. Novel injectable depot formulations
RU2292207C2 (ru) * 2002-10-25 2007-01-27 Пфайзер Продактс Инк. Депо-препараты арилгетероциклических активных веществ в виде суспензии
EP1418492B1 (en) 2002-11-05 2017-09-20 LG Electronics, Inc. Touch screen mounting assembly for LCD monitor
CA2543805A1 (en) 2003-10-24 2005-05-06 Gideon Pilarsky Processes for preparation of ziprasidone
WO2005107719A2 (en) * 2004-05-06 2005-11-17 Sandoz Ag Pharmaceutical composition comprising hydrophobic drug having improved solubility
EP1753400A4 (en) * 2004-06-11 2012-11-28 Reddys Lab Ltd Dr PHARMACEUTICAL FOR ZIPRASIDONE
WO2006085168A2 (en) * 2005-01-07 2006-08-17 Ranbaxy Laboratories Limited Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide
CA2613474A1 (en) * 2005-06-20 2007-03-08 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
EP1906937B1 (en) 2005-07-22 2016-10-19 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
CN100391458C (zh) * 2006-02-07 2008-06-04 上海医药工业研究院 齐拉西酮或其盐包合物制备方法
KR20080076667A (ko) * 2007-02-15 2008-08-20 주식회사 중외제약 요변성 약학 조성물
JP4336380B1 (ja) * 2008-11-06 2009-09-30 塩野義製薬株式会社 水懸濁性を向上させた細粒剤
JP6272730B2 (ja) * 2014-05-21 2018-01-31 救急薬品工業株式会社 速溶性フィルム剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations

Also Published As

Publication number Publication date
TNSN00112A1 (fr) 2005-11-10
IS2396B (is) 2008-08-15
ES2191618T3 (es) 2003-09-16
CN1352560A (zh) 2002-06-05
MA26741A1 (fr) 2004-12-20
BG106153A (bg) 2002-06-28
RS50089B (sr) 2009-01-22
DE60001649T2 (de) 2003-08-21
HK1046366B (zh) 2005-07-29
KR100477782B1 (ko) 2005-03-21
AP2001002346A0 (en) 2001-12-31
HUP0201297A2 (en) 2002-08-28
BG65367B1 (bg) 2008-04-30
EP1181018B1 (en) 2003-03-12
GC0000190A (en) 2006-03-29
EA200101131A1 (ru) 2002-04-25
CU23223B7 (es) 2007-08-30
CA2371550A1 (en) 2000-12-07
UA59491C2 (uk) 2003-09-15
PA8495801A1 (es) 2001-12-14
IS6134A (is) 2001-10-30
DE60001649D1 (de) 2003-04-17
GT200000081A (es) 2001-11-16
JP3942827B2 (ja) 2007-07-11
EE04704B1 (et) 2006-10-16
IL145950A (en) 2007-12-03
CO5170458A1 (es) 2002-06-27
OA11946A (en) 2006-04-13
AP1409A (en) 2005-06-13
EP1181018A1 (en) 2002-02-27
CZ20014230A3 (cs) 2002-08-14
AU4138500A (en) 2000-12-18
PL352826A1 (en) 2003-09-08
AU777413B2 (en) 2004-10-14
EE200100633A (et) 2003-02-17
TWI263498B (en) 2006-10-11
EA003907B1 (ru) 2003-10-30
CR6506A (es) 2004-03-24
HUP0201297A3 (en) 2005-09-28
MY127891A (en) 2006-12-29
UY26166A1 (es) 2000-12-29
HRP20010878B1 (en) 2007-03-31
YU76701A (sh) 2005-07-19
AR022643A1 (es) 2002-09-04
DK1181018T3 (da) 2003-04-22
SV2001000085A (es) 2001-11-08
WO2000072847A1 (en) 2000-12-07
HK1046366A1 (en) 2003-01-10
SK284590B6 (sk) 2005-07-01
JP2003500449A (ja) 2003-01-07
BR0010990A (pt) 2002-03-05
CA2371550C (en) 2007-01-02
SI1181018T1 (en) 2003-06-30
CN1196486C (zh) 2005-04-13
GEP20033113B (en) 2003-11-25
DZ3049A1 (fr) 2004-03-27
IL145950A0 (en) 2002-07-25
TR200103392T2 (tr) 2002-11-21
SK16782001A3 (sk) 2002-09-10
NO20015755D0 (no) 2001-11-26
MXPA01012124A (es) 2002-06-04
PE20010127A1 (es) 2001-02-06
KR20020048307A (ko) 2002-06-22
ATE234097T1 (de) 2003-03-15
ZA200109692B (en) 2002-11-26
NO20015755L (no) 2002-01-23
HN2000000071A (es) 2001-02-02
NZ514764A (en) 2004-04-30
HRP20010878A2 (en) 2003-06-30
PL196867B1 (pl) 2008-02-29

Similar Documents

Publication Publication Date Title
NO320296B1 (no) Oral suspensjon
KR960012397B1 (ko) 시메티딘을 함유하는 조성물
EP0138540B1 (en) Pharmaceutical compositions
JP3465820B2 (ja) トロバフロキサシン経口懸濁剤
US20070134323A1 (en) Ziprasidone suspension
JP4564749B2 (ja) 新規乾燥及び水性エピナスチン−シロップ製剤
CA2323212A1 (en) Process of making an aqueous calcium carbonate suspension
HUT77362A (hu) Sabeluzolt tartalmazó vizes orális szuszpenziók és eljárás előállításukra